Objective. To review the role of intravenous immunoglobulin (IVIg) in antiphospholipid syndrome (APS).
Intravenous immunoglobulins (IVIg) are currently used anticoagulant (LAC ) test on two or more occasions at in autoimmunity for the treatment of immune thromboleast 6 weeks apart] [4]. The manifestations of this cytopenic purpura, Guillain-Barre syndrome, Kawasaki syndrome can further include [5] : venous thrombosisdisease, and polymyositis/dermatomyositis. In addition, deep vein thrombosis, pulmonary thromboembolism, in several other autoimmune conditions there have been Budd-Chiari syndrome, renal vein thrombosis, and several reports about beneficial responses to IVIg ocular thrombosis; arterial thrombosis-stroke, transitherapy, e.g. systemic lupus erythematosus, vasculitis, ent ischaemic attack, amaurosis, myocardial infarction, factor VIII inhibitors [1] [2] [3] . Herein we review the use and limb ischaemia; thrombocytopenia and haemolytic of IVIg for the treatment of patients with antiphosphoanaemia; and other features-epilepsy, migraine, livedo lipid syndrome (APS ).
reticularis, chorea, myelopathy, pulmonary hypertension, skin ulcers, Addison's disease, heart valve disease, and ischaemic necrosis of bone. Pregnancy complica-
APS-definition and clinical manifestations
tions of APS include both maternal (pre-eclampsia/ The definition of APS includes the presence of both eclampsia) and fetal complications (early and late pregclinical and laboratory criteria. In order to diagnose nancy loss, intrauterine growth retardation). Similarly, APS a patient should have at least one clinical manifestaseveral autoantibodies, other than aCL, might be tion (vascular thrombosis, pregnancy morbidity) and detected at APS, and these include antibodies directed one typical serological finding [medium to high titres of to phosphatidylserine (PS), phosphatidylethanolamine anticardiolipin antibodies (aCL) or a positive lupus (PE ), phosphatidylinositol (PI ), phosphatidylglycerol (PG), and phosphatidic acid. These antibodies comprise antibodies directed solely to either beta-2GPI or prothrombin are also found in APS. Hence, the synpregnancy, and lower weights of embryos and placentae than in the control mice [22] . Of specific interest is the drome is termed APS rather than aCL syndrome.
pathogenic role of anti-PS antibodies demonstrated by passive induction of APS by Blank et al. [23] . They
The immunopathogenesis of APS demonstrated the ability of polyclonal aPL to cause adverse effects on pregnancy outcome. Moreover, intraThe association of an autoantibody with clinical manifestations of an autoimmune disease does not necessarily vascular deposition of IgG and fibrin in the uteroplacental interface, absorption of aCL on placentae, and implicate that it is of a pathogenic role. Nevertheless, with respect to antiphospholipid antibodies (aPL), there demonstration of thrombosis in placental vessels, further strengthen the pathogenic role of aPL in APS. Another is good evidence that these antibodies are pathogenic in APS, rather than an epiphenomenon. As one of the way to induce APS is via active induction of disease. In short, when an antibody (Ab1) is either injected or major clinical manifestations of APS is thrombosis, aPL were found to interact with all the components of the generated in response to an autoantigen, its idiotype may stimulate the immune system to produce an anticoagulation system [6 ] . Regarding humoral component involvement, aPL were found to interfere with the body against it (Ab2). Consequently, anti-Ab2 (Ab3) may be generated too, and it can simulate the original activity of protein C, protein S cofactor and antithrombin III [7, 8] , and to inhibit kallikrein formation from autoantibody in its binding characteristics. Thus, following active immunization with a human pathogenic pre-kallikrein [9] . In addition, as beta-2GPI is a natural anticoagulant that inhibits the prothrombinase activity monoclonal IgM aCL (H-3), primary APS developed in BALB/c mice: the mice had high titres of aCL with of platelets [10], binding of aCL to beta-2GPI can disturb its anticoagulant activities and consequently clinical manifestations typical for APS [24] . Similarly, aPL obtained from patients with active APS, as well as increase thrombin generation. Similarly, this antibody can alter the interference of beta-2GPI with ADPmonoclonal antibodies generated from mice with secondary systemic lupus erythematosus, succeeded in induced platelet aggregation [11] . Thus, it has been shown that aCL attenuates the inhibitory effect of active induction of primary APS [25] [26] [27] . In addition, not only did passive transfer of anti-PS succeed in beta-2GPI on the formation of activated factor X in the presence of activated platelets [12] . aPL may also play inducing APS, but active immunization with this antibody also had the same effect [28] . a role in platelet activation in different ways: crossreactivity of aCL with an 80-kDa platelet plasma membrane protein may in turn cause platelet activation [13] , Laboratory evidence for the beneficial effect and similarly aPL can cause shape change and phosof IVIg in APS phorylation of 20-kDa protein that in turn may cause enhancement of thrombosis by increased thromboxane Whereas other therapeutic options in APS inhibit the consequences of aPL activity (e.g. aspirin and heparin A 2 formation, elevated cytosolic calcium concentration, and protein 47-kDa phosphorylation [14] . Furthermore, prevent the APS-associated thrombosis), IVIg both inhibits the aPL themselves, and probably decreases the interaction of aPL with PS on the surface of activated platelets may cause their subsequent destruction and their further production. The inhibitory effect of IVIg on aPL, especially aCL, and LAC has been reported by uptake by the reticulo-endothelial system, which may provide an explanation for the thrombocytopenia charseveral authors [29] [30] [31] [32] . Caccavo et al. [29] reported the inhibition of aCL binding to cardiolipin by F(ab∞) 2 acteristic of APS [15] . With respect to the aPL effect on endothelial cells, increased procoagulant activity of fragment from IVIg in a dose-dependent manner. Similarly, Galli et al. [30] demonstrated dose-dependent endothelial cells and monocytes has been demonstrated in the presence of aPL [16, 17] , and these antibodies inhibition of LAC activity in four patients, using either IVIg or F(ab∞) 2 fragments from it. Finally, partial also enhanced the production of platelet activating factor by endothelial cells [18] . Similarly, decreased neutralization of LAC activity was found in 10 of 11 patient sera following incubation with IVIg [31]. These production of prostaglandin I 2 , which is a potent vasodilator and inhibits platelet aggregation, has been found reports suggest the presence of anti-idiotypes to aPL within IVIg preparations. However, whereas antiin association with LAC [19] . Another possible explanation for the thrombotic tendency in APS is an inhibition idiotypic activity of IVIg is probably the most important mechanism of action of IVIg in the treatment of APS, of anticoagulants by a cross-reaction of aPL with glycosaminoglycans, which are a major component of the nonand it results in short-term neutralization of aPL, it certainly cannot explain the long-term decrease in these thrombogenic lining of the vascular endothelium [20] .
The most convincing evidence for a pathogenic role autoantibody titres. Hence, another mechanism of action of IVIg in APS involves the inactivation of of aPL is their ability to induce APS in vivo in animal models [21] . Passive induction of APS entails the infuidiotype-bearing B cell clones, with the subsequent decrease in autoantibody production. sion of either monoclonal or polyclonal aPL to mice in order to create disease manifestations. Infusion of aCL
The beneficial effect of IVIg in APS has been well demonstrated in animal models of the disease. Infusion (derived either from mice or humans) to pregnant ICR mice resulted in lower fecundity rate, increased resorpof IVIg to mice in which the disease was induced, as previously discussed, resulted in significantly less fetal tion index of embryos, lower number of embryos per resorptions in comparison with untreated mice [33] . Naturally, the case series would be much more valuable in the assessment of IVIg efficacy. Kaaja et al. [47] Similar results were obtained from IVIg treatment of reported three APS patients whose history was remarkexperimentally induced systemic lupus erythematosus able for two pulmonary emboli, 13 miscarriages, and and primary APS [34] : following treatment with either one live-born after pregnancy complicated with preIVIg or F(ab∞) 2 fragments, but not with Fc fragments, eclampsia. The treatment of these three women with a complete clinical remission of both diseases was repetitive doses of IVIg 1 g/kg body weight combined achieved, and it was associated with a decrease in the with daily aspirin 75 mg, resulted in three deliveries of respective autoantibody titres. As anti-idiotypes to aPL healthy babies at term, and one pre-term delivery (at 34 are obviously found within IVIg preparations, the disweeks of gestation). The IVIg therapy was also associcrepancy between the in vitro neutralization of four ated with progressive depression of IgG aCL titre. LAC-positive plasma samples by IVIg, and the neutralSimilar results were reported by Spinnato et al. [48] ization of LAC only in two of these four patients who treated five APS patients (with 17 cumulative following in vivo IVIg administration, led Galli et al. previous unsuccessful pregnancies) with monthly courses [30] to suggest that the clinical efficacy of IVIg in APS of IVIg 2 g/kg body weight beginning in the first or should be attributed to other mechanisms rather than early second trimester. Four of them received concomitanti-idiotypes. This discrepancy can best be explained ant heparin and/or aspirin. This treatment resulted in by the fact that in addition to anti-idiotypes, IVIg four deliveries of healthy babies at term, and one prepreparations also contain aPL [35] . As passive infusion term delivery (at 32 weeks of gestation). A decrease in of aPL succeeded in the induction of experimental APS, IgG aCL titre was observed in three patients. As opposed might IVIg cause an exacerbation of APS rather than to the good clinical outcome of pregnancies in the above clinical improvement of it, or induction of the disease reports, IVIg therapy in six women with recurrent in patients receiving IVIg for another indication? This abortions (five with APS and one with antinuclear question was tested by an animal model that compared antibody) resulted in three complicated twin pregnanthe immunization of mice with pathogenic monoclonal cies, and three pregnancies with intrauterine growth aCL, and the immunization with IVIg containing aPL retardation [49] . However, following each IVIg infusion [35] . In both cases the mice developed high levels of both IgG and IgM aCL titres significantly decreased. In aPL, but whereas the mice immunized with pathogenic a larger case series, Valensise et al. [50] reported 14 APS aCL had thrombocytopenia, prolonged APTT and patients who received IVIg 1 g/kg body weight every 4 higher resorption rate, the mice immunized with IVIg weeks from the 5th to the 33rd week of gestation. did not express the clinical manifestations of APS.
Complications occurred in only one patient who had Therefore, the aPL within IVIg preparations, which also gestational hypertension and abruptio placentae, while have lower affinity to their respective antigens compared in the remaining 13 no maternal, fetal or neonatal with pathogenic aPL, should be considered as natural complications were found, and the median birth weight autoantibodies.
was 3433 g. Similarly, a live-birth rate of 84% in 19 pregnancies of 15 patients with APS treated with monthly IVIg courses beginning in the first or early Clinical use of IVIg in APS second trimester was reported by Clark et al. [51] . Preeclampsia occurred in 25% of the pregnancies, 75% of Most of the reports about the use of IVIg in human the infants were delivered at 34 weeks of gestation or APS focused on its obstetric complications, mainly later, there were no cases of intrauterine fetal growth recurrent pregnancy loss. Nonetheless, there are a few retardation, and in seven pregnancies the IgG aCL titre case reports about treatments of other clinical manifestadecreased. In another report, 38 women with APS and tions of the syndrome (mainly haematological ), and at least three consecutive first trimester spontaneous these are summarized in Table 1 . The first report of IVIg abortions were treated with IVIg 300 mg/kg body weight use for recurrent pregnancy loss was probably that of at 3-week intervals beginning as soon as pregnancy had Carreras et al. [42] who reported a patient with a history been confirmed until the 16th-17th week of pregnancy of nine recurrent abortions, who following a 5-day [52] . In 34 of 38 (89.4%) the pregnancy proceeded course of 400 mg/kg body weight of IVIg at 17 weeks beyond the first trimester, while 31 of 38 (81.4%) gave of gestation, followed by 2-day courses at 22 and 27 birth to a healthy child at term. weeks of gestation gave birth to a healthy girl at 34 The clinical manifestations associated with aPL proweeks of gestation. This report was followed by several gressively expand [53] , and one of these clinical entities other case reports of successful pregnancy outcome in is infertility, as most studies report an increased preval-APS patients with previous habitual abortions [ [43] [44] [45] [46] . ence of aPL in infertile women [54] . Sher et al. [55] However, these cases varied much with respect to dose tested whether aPL-positive infertile women undergoing of IVIg, time of administration, and concomitant therain vitro fertilization (IVF ) could benefit more from IVIg. pies used (e.g. heparin, aspirin, prednisone). Of special Their population study included 89 infertile women who interest is the report of Ron-el et al. [46 ] of a patient had experienced at least four IVF/embryo transfer failwith recurrent fetal loss, in whom a combined treatment ures, of whom 52 were aPL positive and 37 were aPL with IVIg, aspirin and heparin, succeeded in the delivery negative. All 89 patients received daily aspirin 81 mg, daily heparin 10 000 U, and a single infusion of IVIg of a healthy baby after transfer of frozen embryos. Sturfelt et al. [36 ] Thrombocytopenia Successful treatment with IVIg after treatment failure with steroids and cytostatic drugs Cohen and Lui [37] Haemolytic anaemia, thrombocytopenia, Steroids, plasma exchange, IVIg and thrombosis, pulmonary haemorrhage cyclophosphamide did not control disease manifestations whereas low-dose aspirin rapidly corrected anaemia and thrombocytopenia Takagi and Shigekiyo [38] Bleeding associated with thrombocytopenia IVIg therapy resulted in disappearance of LAC activity and increase in platelet count Arnout et al. [39] Habitual abortions, thrombocytopenia IVIg therapy resulted in pre-term labour of baby in good health, and elevated platelet count Vandenberghe et al. [40] Autoimmune haemolytic anaemia Several courses of IVIg succeeded in control of haemolysis Vivaldi et al. [41] Acquired hypoprothrombinaemia-LAC syndrome IVIg and steroids resulted in correction of prothrombin time aClinical manifestations for which IVIg was administered, not necessarily including the entire clinical spectrum in these patients.
20 g 3-10 days before egg retrieval. Twenty-two of 52 which may affect the fate of the embryo. Anticoagulation would probably have no effect on these mechanisms of (42%) aPL-positive women achieved live births compared with seven of 37 (19%) of the aPL-negative women action of aPL, whereas IVIg that neutralizes these antibodies might have. Hence, in the current available (P = 0.02). In another study [56 ] , these authors found that among 687 aPL-positive women undergoing IVF, therapeutic options, more data should be obtained in order to decide when to use anticoagulation, IVIg or birth rates were significantly higher when aspirin and heparin were administered as compared with no antiboth in the treatment of APS. coagulation (46% vs 17%). Further, within the group of women who received aspirin and heparin, birth rates References were significantly lower for women whose aPL were IgG or IgM directed to PS or PE, compared with women
